Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 17/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776894 | 0.85 | GABRA5 (0.53) | GABRA5ITGA5POLB | |
| SCHEMBL1776792 | 0.82 | GABRA5 (0.51) | GABRA5ITGA5 | |
| SCHEMBL1777154 | 0.79 | GABRA1 (0.50) | GABRA5ITGA5 | |
| SCHEMBL1776297 | 0.79 | GABRA5 (0.64) | GABRA5ALDH1A1MAPTNPSR1 | |
| SCHEMBL1777400 | 0.78 | GABRA5 (0.66) | GABRA5ITGA5 | |
| SCHEMBL1776605 | 0.77 | GABRA5 (0.57) | GABRA5ALDH1A1 | |
| SCHEMBL21590639 | 0.76 | GABRA5 (0.56) | GABRA5ITGA5POLBALDH1A1MAPT | |
| SCHEMBL1775732 | 0.75 | GABRA5 (0.55) | GABRA5ITGA5POLBALDH1A1MAPT | |
| SCHEMBL1776320 | 0.75 | GABRA5 (0.58) | GABRA5ITGA5POLBALDH1A1MAPT | |
| SCHEMBL1777214 | 0.73 | GABRA5 (0.60) | GABRA5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231651-B1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-11-21 | — | — | EP | disclosed |
| US-7943619-B2 | Isoxazolo-pyridazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2231651-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009071477-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-11 | — | — | WO | disclosed |
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | GABRA5, CHRNA5, GABRA1 | GABRA5 1/4885ITGA5 229/4885POLB 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.